CIK 0001178670 · Large accelerated filer
ALNYLAM PHARMACEUTICALS, INC.
Sign in to watch- Ticker
- ALNY
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Entity type
- operating
- EIN
- 770602661
- Phone
- (617) 551-8200
- Business address
- 675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, 02142
- Former names
- ALNYLAM PHARMACEUTICALS INC
- Open-market buys, last 90 days
- $543,126
- in 2 filings
- Open-market sales, last 90 days
- $398,855
- in 1 filing
Net +$144,271. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-03-03 | Fitzgerald Kevin Joseph CSO & EVP, Head of Research | Sale 10b5-1 | −289 | $316.55 | $91K | 23,223 |
| 2026-03-03 | Fitzgerald Kevin Joseph CSO & EVP, Head of Research | Sale 10b5-1 | −282 | $318.62 | $90K | 22,941 |
| 2026-03-03 | Fitzgerald Kevin Joseph CSO & EVP, Head of Research | Sale 10b5-1 | −722 | $320.51 | $231K | 22,219 |
| 2026-03-03 | Fitzgerald Kevin Joseph CSO & EVP, Head of Research | Sale 10b5-1 | −359 | $321.58 | $115K | 21,860 |
| 2026-03-02 | Poulton Jeffrey V. EVP, Chief Financial Officer | Grant or award | +4,769 | 66,479 | ||
| 2026-03-02 | Poulton Jeffrey V. EVP, Chief Financial Officer | Sale | −65 | $323.62 | $21K | 66,414 |
| 2026-03-02 | Poulton Jeffrey V. EVP, Chief Financial Officer | Sale | −124 | $324.65 | $40K | 66,290 |
| 2026-03-02 | Poulton Jeffrey V. EVP, Chief Financial Officer | Sale | −356 | $325.63 | $116K | 65,934 |
| 2026-03-02 | Poulton Jeffrey V. EVP, Chief Financial Officer | Sale | −541 | $326.81 | $177K | 65,393 |
| 2026-03-02 | Poulton Jeffrey V. EVP, Chief Financial Officer | Sale | −454 | $327.67 | $149K | 64,939 |
| 2026-03-02 | Poulton Jeffrey V. EVP, Chief Financial Officer | Sale | −138 | $328.71 | $45K | 64,801 |
| 2026-03-02 | Poulton Jeffrey V. EVP, Chief Financial Officer | Sale | −234 | $329.71 | $77K | 64,567 |
| 2026-03-02 | Poulton Jeffrey V. EVP, Chief Financial Officer | Sale | −112 | $330.85 | $37K | 64,455 |
| 2026-03-02 | Poulton Jeffrey V. EVP, Chief Financial Officer | Sale | −129 | $331.93 | $43K | 64,326 |
| 2026-03-02 | Poulton Jeffrey V. EVP, Chief Financial Officer | Sale | −53 | $332.64 | $18K | 64,273 |
| 2026-03-02 | Poulton Jeffrey V. EVP, Chief Financial Officer | Grant or award · Stock Option (right to buy) | +10,480 | 10,480 | ||
| 2026-03-02 | Garg Pushkal EVP Chief R&D | Grant or award 10b5-1 | +4,769 | 26,898 | ||
| 2026-03-02 | Garg Pushkal EVP Chief R&D | Sale 10b5-1 | −50 | $323.62 | $16K | 26,848 |
| 2026-03-02 | Garg Pushkal EVP Chief R&D | Sale 10b5-1 | −97 | $324.65 | $31K | 26,751 |
| 2026-03-02 | Garg Pushkal EVP Chief R&D | Sale 10b5-1 | −277 | $325.63 | $90K | 26,474 |
Page 6 of 41 · 816 trades